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Mammalian UDP-glucuronosyltransferases (UGTs) catalyze the transfer of glucuronic
acid from UDP-glucuronic acid to various xenobiotics and endobiotics. Since
UGTs comprise rate-limiting enzymes for metabolism of various compounds, co-
administration of UGT-inhibiting drugs and genetic deficiency of UGT genes can cause
an increased blood concentration of these compounds. During the last few decades,
extensive efforts have been made to advance the understanding of gene structure,
function, substrate specificity, and inhibition/induction properties of UGTs. However,
molecular mechanisms and physiological importance of the oligomerization and protein–
protein interactions of UGTs are still largely unknown. While three-dimensional structures
of human UGTs can be useful to reveal the details of oligomerization and protein–
protein interactions of UGTs, little is known about the protein structures of human
UGTs due to the difficulty in solving crystal structures of membrane-bound proteins.
Meanwhile, soluble forms of plant and bacterial UGTs as well as a partial domain of
human UGT2B7 have been crystallized and enabled us to predict three-dimensional
structures of human UGTs using a homology-modeling technique. The homology-
modeled structures of human UGTs do not only provide the detailed information about
substrate binding or substrate specificity in human UGTs, but also contribute with unique
knowledge on oligomerization and protein–protein interactions of UGTs. Furthermore,
various in vitro approaches indicate that UGT-mediated glucuronidation is involved in
cell death, apoptosis, and oxidative stress as well. In the present review article, recent
understandings of UGT protein structures as well as physiological importance of the
oligomerization and protein–protein interactions of human UGTs are discussed.
Keywords: UDP-glucuronosyltransferase (UGT), protein–protein interactions, glucuronidation, glucuronides,
drug-metabolizing enzymes
INTRODUCTION
Humans are exposed on a daily basis to xenobiotics that may potentially be toxic or
pharmacologically active. Xenobiotics are often hydrophobic and therefore may accumulate
in the body. To facilitate the excretion of xenobiotics, detoxifying enzymes metabolize them
mostly in the liver to increase their hydrophilicity. Since such xenobiotic-metabolizing enzymes
play an important role in the metabolism of clinically used drugs, they are also called drug-
metabolizing enzymes. Phase I drug-metabolizing enzymes, such as cytochrome P450s (CYPs) and
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esterases, catalyze oxidation, reduction, and hydrolysis of
xenobiotics (Satoh and Hosokawa, 1998; Nebert and Russell,
2002). The formed metabolites, as well as parental compounds,
are further metabolized by phase II drug-metabolizing enzymes,
such as UDP-glucuronosyltransferases (UGTs), sulfotransferases,
and glutathione S-transferases (Jancova et al., 2010; Miners et al.,
2010). Among these, UGTs have been reported with the highest
contribution to drug metabolism (Williams et al., 2004).
UDP-glucuronosyltransferases-mediated glucuronidation can
be a rate-limiting step in the clearance of endogenous and
exogenous substances. Therefore, inhibition of UGTs by co-
administered drugs or genetic deficiency in the UGT gene
can increase blood concentrations of their substrates in vivo,
whereas induction of UGT genes would result in a decrease of
blood concentrations of their substrates (Lankisch et al., 2009;
Hirashima et al., 2016). Three-dimensional crystal structures
are useful to facilitate the understanding of protein structures
that determine substrate- and/or inhibitor-binding. Due to the
difficulty in obtaining the crystal structure of membrane proteins,
entire three-dimensional structures of human UGTs have not
been determined except for a partial domain of human UGT
(Miley et al., 2007). On the other hand, entire crystal structures
of soluble forms of plant and bacterial UGTs have previously
been reported (Mulichak et al., 2003; Shi et al., 2014). These
solved structures were used as templates of homology modeling
of human UGTs (Fujiwara et al., 2009a). Although amino acid
similarities are not high between mammalian and plant/bacterial
UGTs, the modeled human UGT structures are comparable
to plant and bacterial UGTs, suggesting that the structures of
plant/bacterial UGTs may aid in the structural clarification of
human UGTs.
UDP-glucuronosyltransferases enzymes comprise a
superfamily. One of the most unique and important properties
of UGTs is that they form homo- and hetero-oligomers such
as dimers, trimers, and tetramers (Finel and Kurkela, 2008).
Tukey and Tephly (1981) were the first to report that rat
UGTs functioned in an oligomeric form. Subsequently, various
in vitro techniques such as cross-linking and fluorescence
resonance energy transfer (FRET) imaging demonstrated the
oligomerization of UGT proteins (Ikushiro et al., 1997; Operaña
and Tukey, 2007). Interestingly, accumulating evidence indicates
that UGT–UGT interactions affect their enzymatic activities
(Ishii et al., 2001; Fujiwara et al., 2007a,b). Analyses using
the homology-modeled UGT structures further revealed the
region responsible for the oligomerization of UGTs (Lewis
et al., 2011). Moreover, specific antibodies against UGTs
immunoprecipitated not only UGTs but also CYPs in human
liver microsomes, indicating that UGTs appeared to interact with
other microsomal proteins (Fujiwara and Itoh, 2014). Indeed,
recently developed techniques such as mass spectrometry analysis
of immunoprecipitates revealed that UGTs may interact with
a variety of microsomal proteins including epoxide hydrolase
1, carboxylesterase 1, alcohol dehydrogenases, and glutathione
S-transferases (Fujiwara and Itoh, 2014).
In this review article, recent advances in the knowledge on
the three-dimensional structure, protein interactions of human
UGTs, and physiological roles of UGTs are introduced along with
early and recent analytical tools that demonstrate the presence of
UGT oligomers.
UDP-GLUCURONOSYLTRANSFERASE
(UGT)
Human UGT Families and Their Function
UDP-Glucuronosyltransferase (UGT, EC 2.4.1.17), which
belongs to a large glycosyltransferase (GT) 1 family of GTs
(EC 2.4.1.-; GT), is a family of membrane-bound proteins that
catalyze a transfer of glucuronic acid from UDP-glucuronic acid
to various endogenous and exogenous substances (Figure 1)
(Mackenzie et al., 2005). UGTs are specifically expressed in
the ER and most the UGTs are localized in the luminal side of
the ER-membrane, which is rich in UDP-glucuronic acid. In
humans, the UGT gene superfamily contains UGT1 and UGT2.
The single human UGT1 gene, located on chromosome
2q37.1, contains multiple exon 1s and common exons 2–5,
spanning approximately 200 kbp. Individual UGT1 isoforms,
UGT1A1, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7,
UGT1A8, UGT1A9, and UGT1A10, are generated by exon
sharing of the UGT1 gene (Figure 2A). Importantly, Dr. Girard
et al. (2007) discovered that there are two types of exon 5,
exons 5a and 5b, which encodes a shorter amino acid sequence.
Compared to 50–55 kDa proteins encoded by exons 1–4 and 5a
(UGT1A_i1), which is a main variant, the proteins encoded by
exons 1–4 and 5b (UGT1A_i2) are smaller (45 kDa) and generally
exhibit lower enzymatic activities.
Human UGT2 genes, including UGT2A and UGT2B, are
located on chromosome 4q13.2. UGT2A1 and UGT2A2 are
generated by exon sharing of unique exon 1s and common exons
2–6 of the UGT2A gene in the same manner as UGT1A proteins,
whereas a single gene encodes UGT2A3. UGT2B family proteins,
UGT2B4, UGT2B7, UGT2B10, UGT2B11, UGT2B15, UGT2B17,
and UGT2B28, are encoded by each unique gene in a cluster
(Figure 2B). Transcriptional diversity has been reported in the
UGT2B7 locus. Original six exons as well as extra three exon
1s and two exon 6s of the UGT2B7 gene can produce up to 22
transcript variants which encode 7 types of UGT2B7 proteins
(UGT2B7_i1 to _i7) (Ménard et al., 2011). Similar to UGT1A_i1,
UGT2B7_i1 exhibits the highest enzyme activity compared
to UGT2B7_i2 to _i7 proteins. Recently conducted targeted
RNA next-generation sequencing revealed that transcriptional
diversity, such as new internal exons and exon skipping, could
be observed in other UGT2B genes (Tourancheau et al., 2016).
The expression and enzyme activities of such alternative UGT2Bs
need to be determined in the future.
Tissue Distribution of UGTs
In humans, all of 9 UGT1 and 10 UGT2 isoforms are
expressed in a tissue-specific manner. In the liver, which is the
most important tissue in metabolism of xenobiotics, UGT1A1,
UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B4, UGT2B7,
UGT2B10, UGT2B15, and UGT2B17 are expressed (Nakamura
et al., 2008; Izukawa et al., 2009). UGT1A8 and UGT1A10 are
mainly expressed in the small intestine, colon, and bladder.
Frontiers in Pharmacology | www.frontiersin.org 2 October 2016 | Volume 7 | Article 388
fphar-07-00388 October 20, 2016 Time: 17:9 # 3
Fujiwara et al. Structure and Protein–Protein Interactions of Human UGTs
FIGURE 1 | Conjugation reaction catalyzed by UDP-glucuronosyltransferases (UGTs). UGTs catalyze the transfer of glucuronic acid from UDP-glucuronic
acid to an oxygen, nitrogen, or sulfur atom of their substrates. (R = substrate).
FIGURE 2 | Gene structures of human UGT1 and UGT2. (A) Human UGT1 gene contains multiple exon 1s and common exons 2–5, and each UGT1 isoform are
generated by exon sharing of the gene. Exon 5a produces UGT1A_i1 proteins, while exon 5b produced smaller UGT1A_i2 proteins. (B) UGT2A1 and UGT2A2 are
generated by exon sharing of unique exon 1s and common exons 2–6 of the UGT2A gene in the same manner as UGT1A proteins. UGT2A3 and UGT2B family
proteins are encoded by each unique gene in a cluster.
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UGT1A7 has been characterized as an isoform that is specifically
expressed in the stomach (Strassburg et al., 1997). In the
kidneys, UGT1A9 and UGT2B7 are highly and other UGTs
such as UGT1A4, UGT1A6, and UGT2B11 are moderately
expressed. The expression of UGT2B28 is limited to the bladder,
where various UGT1 and UGT2 members are also expressed.
UGT2A1 and UGT2A2 are expressed in nasal tissue, whereas
UGT2A3 is expressed mainly in liver and small intestine, and
slightly in lung and nasal tissues (Sneitz et al., 2009). Since
UGT2A family isoforms glucuronidate endogenous substances
rather than drugs, it has been believed that they have certain
physiological role in those organs, although more investigation
is required.
Substrate Specificity of UGTs
UDP-glucuronosyltransferases catalyze the transfer of glucuronic
acid from UDP-glucuronic acid to an oxygen, nitrogen, or sulfur
atom in their substrates (Figure 1). UGT1A1 glucuronidates
relatively bulky molecules such as bilirubin, SN-38, and
etoposide, as well as planar or smaller molecules such as estradiol,
1-naphthol, and 4-methylumbelliferone (Bosma et al., 1994;
Watanabe et al., 2003; Mano et al., 2004). While these smaller
compounds can be glucuronidated by several other UGT1 and
UGT2 family proteins, bilirubin is solely glucuronidated by
UGT1A1 (Bosma et al., 1994). UGT1A4 has been recognized as
one of the UGT isoforms that can glucuronidate tertiary amines
(e.g., nicotine, imipramine, trifluoperazine, and lamotrigine)
(Kuehl and Murphy, 2003; Smith et al., 2003; Rowland et al.,
2006). A recent study demonstrated that clearances of nicotine,
amitriptyline, imipramine, and diphenhydramine by UGT2B10-
mediated N-glucuronidation were significantly higher than those
by UGT1A3 and UGT1A4, indicating that UGT2B10 plays
an important role in N-glucuronidation of certain amine-
containing compounds (Kato et al., 2013). As UGT1A6 was
originally characterized as a phenol-glucuronidating enzyme,
it mainly glucuronidates small phenolic substances such as 4-
nitrophenol, 1-naphthol, and 4-methylumbelliferone (Hanioka
et al., 2001). 5-Hydroxytriptamine, also called serotonin, has been
recognized as a specific substrate of UGT1A6 (Krishnaswamy
et al., 2003). UGT1A9 metabolizes a wide variety of substances
such as mycophenolic acid, scopoletin, and entacapone (Kurkela
et al., 2003; Bernard and Guillemette, 2004). Propofol has
been used as a selective substrate of UGT1A9 in the livers,
although it can also be glucuronidated by UGT1A7, UGT1A8,
and UGT1A10 in the gastrointestine (Court, 2005). UGT2B
isoforms are especially important in the glucuronidation of
endogenous compounds such as androsterone, testosterone, and
dihydrotestosterone. Zidovudine and morphine are specifically
metabolized by UGT2B7 (Barbier et al., 2000). It has been shown
that UGT2B15 is the major enzyme responsible for sipoglitazar
glucuronidation in humans, while multiple UGT1A and UGT2B
members slightly glucuronidate sipoglitazar (Nishihara et al.,
2013). UGT2B17, which has more than 95% homology with
UGT2B15, can glucuronidate a wide variety of exogenous and
endogenous compounds, including coumarins, anthraquinones,
flavonoids, and androgens (Turgeon et al., 2003). Therefore, each
UGT isoform exhibits broad but distinct substrate specificities.
Significance of Extrahepatic UGTs
Because bilirubin is solely glucuronidated by UGT1A1, genetic
deficiency in the UGT1A1 gene can result in an onset of
severe hyperbilirubinemia (>20 mg/dL serum bilirubin) in
humans (Beutler et al., 1998). Knockout of Ugt1a1 in mice
causes very severe hyperbilirubinemia (>15 mg/dL serum
bilirubin), which is lethal within 11 days of birth due to the
development of kernicterus (Nguyen et al., 2008). Since UGT1A1
is highly expressed in the liver, it was previously commonly
believed that hepatic UGT1A1 mainly contribute to the bilirubin
glucuronidation. However, a recent study demonstrated that
liver-specific knockout of the Ugt1 gene, including Ugt1a1,
resulted in a mild increase of serum bilirubin (2 mg/dL
serum bilirubin; Chen et al., 2013). Furthermore, increased
expressions of intestinal UGT1A1 lead to decreased serum
bilirubin levels (from 12 to 2 mg/dL) in 14-day-old humanized
UGT1 mice, indicating that intestinal UGT1A1 also plays an
important role in bilirubin metabolism (Fujiwara et al., 2010b,
2012). UGT1A1 expressed in the skin and brain might also
be responsible for bilirubin metabolism in neonates although
to a lesser extent (Sumida et al., 2013; Kutsuno et al., 2015).
In addition to UGT1A1, substantial expression of UGT1A8
and UGT1A10 mRNA are also observed in the small intestine
(Nakamura et al., 2008). Since recombinant UGT1A1, UGT1A8,
and UGT1A10 glucuronidate raloxifene in vitro, these enzymes
might be responsible for the extremely poor oral bioavailability of
raloxifene (Mizuma, 2009). However, it should be noted that the
UGT1A8 protein was barely detected in human small intestine in
a targeted peptide-based quantification study (Sato et al., 2014).
Therefore, the role of UGT1A8 in intestinal glucuronidation
in vivo needs to be carefully investigated in the future. These
data support a concept that in addition to hepatic UGTs,
extrahepatic UGTs also play a dominant role in glucuronidation
of endogenous and exogenous compounds (Fujiwara et al., 2015).
THREE-DIMENSIONAL STRUCTURE OF
HUMAN UGTs
Structure of Glycosyltransferase 1
Family Protein
Due to difficulties in crystallizing membrane-bound protein,
X-ray crystal structures of membrane-bound human UGTs
have not been determined. As mentioned above, human
UGTs belong to a large glycosyltransferase (GT) 1 family.
Because plant and bacterial GT1 family proteins are soluble
forms, several X-ray crystal structures of plant and bacterial
GTs have successfully been determined. In 2003, a 2.8-Å
crystal structure of TDP-epi-vancosaminyltransferase (GtfA),
which is one of the GT1 family proteins that transfer 4-epi-
vancosamine from TDP-epi-vancosamine to its substrate, in
Amycolatopsis orientalis was solved (Mulichak et al., 2003).
The crystal structure (PDB ID: 1PN3) revealed that GtfA
adopts a GT-B fold that consists of two separate Rossmann
domains with a connecting linker and a catalytic cleft. In
addition, other GT1 family proteins such as plant UDP-glucose
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flavanoid 3-O glucosyltransferase (2C1X) and multifunctional
triterpene/flavonoid glycosyltransferase UGT71G1 (2ACV) also
have the GT-B fold (Shao et al., 2005; Offen et al., 2006). These
findings lead us to hypothesize that human UGTs would also be
GT-B fold enzymes.
Predicted Structure of Human UGTs
Human UGT1 and UGT2 family members consist of
approximately 530 amino acids. One of the unique properties of
UGTs is that they sometimes recognize overlapping but specific
substrates, while they commonly recognize a co-substrate UDP-
glucuronic acid (Mackenzie et al., 2005). Because UGT1 family
proteins are generated by exon sharing of the single UGT1 gene
(Figure 2A), their C-terminal amino acid sequences encoded
by the common exons 2–5 are identical. Although UGT2 family
proteins are encoded by their individual genes (Figure 2B), the
C-terminal amino acid sequences exhibit extremely high amino
acid similarity. In contrast, the N-terminal amino acid sequences
of UGT1 and UGT2 family members exhibit relatively lower
amino acid similarity. For example, the sequence homology is
24–49% between N-terminal regions of UGT1 family enzymes
(Mackenzie et al., 1997). Point mutation analyses demonstrated
that mutations in the N- and C-terminal halves dramatically
decreased the affinities toward substrates and UDP-glucuronic
acid, respectively (Xiong et al., 2006; Patana et al., 2007; Fujiwara
et al., 2009b; Kerdpin et al., 2009). These mutagenesis studies
support an assumption that human UGTs have two domains,
the highly conserved C-terminal halves responsible for the
UDP-glucuronic acid binding and the unique N-terminal halves
responsible for the substrate binding. A 1.8-Å resolution apo
crystal structure of the C-terminal half of human UGT2B7
(2O6L), which is a solely available X-ray crystal structure of
human UGTs, confirmed that the C-terminal domain contained
a preserved nucleotide-sugar binding site (Miley et al., 2007).
Homology-Modeled Structure of Human
UGTs
Three-dimensional structures of unsolved proteins can be
modeled by homology-modeling. Locuson and Tracy (2007)
conducted homology modeling of human UGT1A1 using the
crystallized structure of plant UGT71G1 (2ACV) as a template.
The length of the amino acid sequence of human UGT1A1 (533
amino acids) is relatively longer than that of plant UGT71G1
(463 amino acids). The amino acid similarity between UGT1A1
and UGT71G1 is 34%, but it was sufficient to obtain a reliable
homology-model. The overall three-dimensional structure of
UGT1A1 showed two Rossmann fold-like domains (Locuson and
Tracy, 2007). Banerjee et al. (2008) modeled a three-dimensional
structure of human UGT1A10 using UDP-galactose 4-epimerase
(1XEL) from Escherichia coli as a template structure (Banerjee
et al., 2008). The modeled structures of substrate- and UDP
sugar-binding pockets were overlapped well with those of the
template structure. The structural analysis indicated that lysine
residues at 314 and 404 (K314 and K404) would play a critical
role in the UDP-glucuronic acid binding of UGT1A10. They
confirmed, by in vitro mutagenesis analysis, the importance of
K314 and K404 in the UDP-glucuronic acid binding. Therefore,
the homology-modeled structures of human UGTs are relatively
reliable, even though the amino acid similarities are not high
between human and plant/bacteria UGTs. Similar homology-
modeling approaches have been carried out by many research
groups to simulate the three dimensional structures of human
UGTs (Table 1). Structural similarity of C-terminal domains was
very high between the modeled structures and the crystallized
structure of the C-terminal half of human UGT2B7 (2O6L),
supporting the reliability of the homology-modeling technique
(Figure 3).
Among the 19 functional human UGT proteins, UGT1A9
exhibits several unique properties. In 2007, we demonstrated that
UGT1A9 was uniquely stable against heat treatment, while the
other human UGTs lost their enzymatic activities when incubated
at higher temperature (Fujiwara et al., 2007b). Importantly, 13
amino acid residues were found to be specific to UGT1A9 among
9 UGT1A isoforms. To examine the role of these residues in the
thermal stability of UGT1A9, we conducted molecular dynamics
simulation of homology-modeled structures of UGT1A9 as well
as UGT1A8 as a reference at higher and lower temperatures.
The in silico simulation revealed that the UGT1A9-specific
residues were collectively involved in the thermal stability of
UGT1A9 (Fujiwara et al., 2009b). In vitro mutagenesis analysis
confirmed that the UGT1A9-specific residues, Arg42, Lys91,
Ala92, Tyr106, Gly111, Tyr113, Asp115, Asn152, Leu173, Leu219,
His221, Arg222, and Glu241, contributed to protein stability.
Since the results of in silico and in vitro analyses were consistent,
it is considered that the homology-modeled structure of human
UGT1A9 (Figure 3) was relatively reliable.
DIMERIZATION AND OLIGOMERIZATION
OF UGTs
The first evidence to demonstrate the oligomerization of
mammalian UGTs was reported by Tukey and Tephly (1981).
Shortly after the publication, Matern et al. (1982) demonstrated
oligomeric UGTs in . Subsequently, a number of research
groups showed that mammalian UGTs including human UGTs
formed homo- and hetero-oligomers such as dimers, trimers, and
tetramers. In this section, earlier and recent analytical tools used
to show the oligomeric UGTs are summarized.
Gel Permeation Chromatography
Tukey and Tephly (1981) purified two different UGT isoforms,
which mediate estrone and p-nitrophenol glucuronidations,
respectively, from rabbit liver microsomes by DEAE-cellulose
chromatography and affinity chromatography on UDP-
hexanolamine Sepharose-4B. Both enzymes exhibited molecular
weights of 57 kDa in the SDS-PAGE analysis. Interestingly,
a gel filtration study of the purified UGT isoforms by an
Ultragel AcA 34 column revealed that both UGTs had apparent
molecular weights of 230 kDa (Tukey and Tephly, 1981), which
is approximately 4 times larger than the size of monomeric
UGTs. This was the first report demonstrating that mammalian
UGTs could be present as tetramers.
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TABLE 1 | Homology modeled human UDP-glucuronosyltransferases (UGTs) and their template structures.
Modeled UGT Template Template PDB ID Reference
UGT1A1 Medicago truncatula triterpene UDP-glucosyl transferase (UGT71G1) 2ACV Locuson and Tracy, 2007
UGT1A1 Medicago truncatula triterpene UDP-glucosyl transferase (UGT71G1) 2ACV Li and Wu, 2007
UGT1A1 Arabidopsis thaliana hydroquinone glucosyltransferase (UGT72B1) 2VCE Laakkonen and Finel, 2010
Amycolatopsis orientalis UDP-glycosyltransferase (GtfB) 1IIR
Streptomyces antibioticus oleandomycin glycosyltransferase 2IYA
Homo sapiens UGT2B7 (C-terminal domain) 2O6L
UGT1A1 Arabidopsis thaliana hydroquinone glucosyltransferase (UGT72B1) 2VCE Song et al., 2015
Streptomyces antibioticus oleandomycin glycosyltransferase 2IYA
Vitis vinifera UDP-glucose flavonoid 3-o-glycosyltransferase (VvGTl) 2C1X
UGT1A3 Medicago truncatula multifunctional (iso)flavonoid glycosyltransferase (UGT85H2) 2PQ6 Song et al., 2015
Vitis vinifera UDP-glucose flavonoid 3-o-glycosyltransferase (VvGTl) 2C1X
Medicago truncatula Flavonoid 3-o-glucosyltransferase (UGT78G1) 3HBF
UGT1A3 Streptomyces antibioticus oleandomycin glycosyltransferase 2IYA Yao et al., 2015; Liu X. et al., 2016
Vitis vinifera UDP-glucose flavonoid 3-o glycosyltransferase (VvGTl) 2C1X
Arabidopsis thaliana hydroquinone glucosyltransferase (UGT72B1) 2VCE
UGT1A3 Vitis vinifera UDP-glucose flavonoid 3-o glycosyltransferase (VvGTl) 2C1Z Schirris et al., 2015
UGT1A8 and UGT1A9 Amycolatopsis orientalis TDP-epi-vancosaminyltransferase (GtfA) 1PN3 Fujiwara et al., 2009a
UGT1A9 Vitis vinifera UDP-glucose flavonoid 3-o-glycosyltransferase (VvGTl) 2C1Z Wu et al., 2012
UGT1A9 Vitis vinifera UDP-glucose flavonoid 3-o-glycosyltransferase (VvGTl) 2C1Z Li et al., 2016
Homo sapiens UGT2B7 (C-terminal domain) 2O6L
UGT1A9 and UGT1A10 Streptomyces antibioticus oleandomycin glycosyltransferase 2IYA Tripathi et al., 2016
Streptomyces fradiae C-glycosyltransferase (UrdGT2) 2P6P
Medicago truncatula triterpene UDP-glucosyl transferase (UGT71G1) 2ACV
Homo sapiens UGT2B7 (C-terminal domain) 2O6L
UGT1A10 Escherichia coli UDP-galactose 4-epimerase 1XEL Banerjee et al., 2008
UGT2B7 Vitis vinifera UDP-glucose flavonoid 3-o-glycosyltransferase (VvGTl) 2C1X, 2C1Z, 2C9Z Lewis et al., 2011; Chau et al., 2014
Medicago truncatula triterpene UDP-glucosyl transferase (UGT71G1) 2ACV, 2ACW
Homo sapiens UGT2B7 (C-terminal domain) 2O6L
UGT2B7 Streptomyces antibioticus oleandomycin glycosyltransferase 2IYA Zhang et al., 2016
Medicago truncatula multifunctional (iso)flavonoid glycosyltransferase (UGT85H2) 2PQ6
C-terminal domains of
UGT1, UGT2A1/2A2,
UGT2A3, UGT2B4,
UGT2B10, UGT2B11,
UGT2B15, UGT2B17,
UGT2B28
Homo sapiens UGT2B7 (C-terminal domain) 2O6L Nair et al., 2015
Matern et al. (1982) similarly purified UGTs that catalyze
chenodeoxycholic acid and testosterone glucuronidations
from rat liver microsomes by a series of purification steps
such as polyethylene glycol fractionation, DEAE-Sepharose
CL-6B chromatography, UDP-hexanolamine-Sepharose 4B
chromatography, and Bio-Gel A-1.5 m chromatography. While
the molecular weight of subunit was determined to be 54 kDa
in the SDS-PAGE analysis, the apparent molecular weight of
the enzyme was calculated to be 316 kDa in a polyacrylamide
gradient slab gel electrophoresis (Matern et al., 1982). The data
indicated that rat UGTs were also present as tetrameric or even
larger oligomeric forms.
Radiation Inactivation
Radiation inactivation is an analytical tool to determine
molecular weights of membrane-bound enzymes in situ
(Kempner and Schlegel, 1979). Enzymes are inactivated when
they are irradiated with ionizing radiation. The extent of
radiation-induced inactivation of the enzymes is directly
associated with the radiation dose and the molecular weight
of the concerned enzymes. Peters et al. (1984) determined the
molecular weights of rat UGTs by radiation-inactivation of
SDS-treated lyophilized liver microsomes using a calibrated
60Co source. The radiation-inactivation analysis revealed that
bilirubin mono-glucuronidation was catalyzed by a 41.5 kDa
protein, while bilirubin di-glucuronidation was catalyzed by a
175 kDa protein. It was further demonstrated that proteins with
molecular weight of 142 and 159 kDa catalyzed glucuronidations
of testosterone and phenolphthalein, respectively (Peters
et al., 1984). Similarly, the radiation inactivation analysis
by Gschaidmeier and Bock (1994) revealed that molecular
weights of UGTs catalyzing the glucuronidations of 1-naphthol,
6-hydroxychrysene, 3,6-dihydroxybenzo[a]pyrene, and 3,6-
dihydroxychrysene were 91–218 kDa. The series of radiation
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FIGURE 3 | Homology-modeled structures of human UGT1A9 and UGT1A8. Three-dimensional structures of human UGT1A9 and UGT1A8 were
homology-modeled using Amycolatopsis orientalis GtfA (PDB ID: 1PN3) as template structures. The structures of UGT1A9 and UGT1A8 contain two Rossmann
fold-like domains in the N-terminus and C-terminus. The structures are colored from red at the N-terminal to blue at the C-terminal. Amino acid residues that are
predicted to interact with UDPGA and to be important for the catalysis are shown by red and blue licorice, respectively. The X-ray crystal structure of the C-terminal
domain of UGT2B7 was retrieved from the Protein Data Bank (PDB ID: 2O6L). Adapted from Drug Metabolism and Pharmacokinetics (Fujiwara et al., 2009a).
inactivation analyses clearly demonstrated that mammalian
UGTs were functional as oligomeric proteins that are composed
of two to four subunits.
Cross-Linking
In intact cells, most of proteins are interacting with other
protein(s) (Jeong et al., 2001). Upon the denaturing process in
the SDS-PAGE analysis, such protein interactions via disulfide
binding, hydrogen binding, and hydrophobic or salt-bridge
interactions are disrupted, so that the proteins are separated
according to their molecular weight. Cross-linkers are reagents
that can introduce covalent chemical bonds between specific
amino acids of proteins. Thus, proteins treated with cross-
linkers can be observed as bands with higher molecular
weights rather than their monomeric forms on SDS-PAGE
followed by immunoblotting. Ikushiro et al. (1997) used 1,6-
bis(maleimido)hexane (BMH), which is a homobifunctional
cross-linker that reacts with sulfhydryl-groups of proteins. When
rat liver microsomes that were incubated with BMH and were
applied to the SDS-PAGE followed by the immunoblotting
analysis using anti UGT1 or UGT2B1 antibodies, multiple
bands with molecular masses of 50–60 kDa as well as of
120–130 kDa were observed (Ikushiro et al., 1997). They
concluded that sulfhydryl group(s) of rat UGTs are located
on the outside of the proteins and play a critical role in
the formation of UGT dimers. Ghosh et al. (2001) used the
disulfide cross-linker BMH and an amino group cross-linker
dimethyl 3,3′-dithiobispropionimidate (DTBP) to demonstrate
homo-oligomers of human UGT1A1, finding that both BMH
and DTBT produced bands corresponding to homo-dimers
of UGT1A1 on the SDS-PAGE analysis. The density of
the bands was apparently reduced when UGT1A1-expressed
cells were incubated with DTBP at pH 9.0, indicating that
homodimerization of human UGT1A1 can be disrupted at
alkaline pH.
Affinity Purification and
Immunoprecipitations
Immunopurification and immunoprecipitation are classical
methods to identify proteins interacting with a target protein.
When rat liver microsomes were solubilized in buffer containing
1% Emulgen 913 and were applied to a UGT1 antibody-
conjugated Sepharose 4B column, not only UGT1 isozymes
but also unidentified 50-kDa protein(s) were co-eluted by
eluting solution containing UGT1A-peptides (Ikushiro et al.,
1997). Amino acid sequencing of the 50-kDa proteins and
immunoblotting studies further revealed that the protein
interacting with UGT1A was UGT2B1. Although the method
used in a study by Kurkela et al. (2003) was Ni-column which
is not immunopurification, they purified homo-oligomer of
UGT1A9 that consisted of His- and hemagglutinin (HA)-tagged
UGT1A9.
Fremont et al. (2005) conducted immunoprecipitation assays
to examine protein–protein interactions between UGT1A1,
UGT1A6, and UGT2B7 in human liver microsomes. When
solubilized microsomes were incubated with UGT1A1-,
UGT1A6-, and UGT2B7-specific antibodies, not only the
antigenic proteins but also other UGT isozymes were co-
immunoprecipitated. In 2007, we established cell lines that are
individually or simultaneously expressing human UGT1A6
and UGT1A9 (Fujiwara et al., 2007b). A human UGT1A6-
specific antibody co-immunoprecipitated UGT1A9, as well
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as UGT1A6, in the UGT1A6-UGT1A9 double expression
cells, although it did not immunoprecipitate UGT1A9 in the
UGT1A9-expressed cells. When cyan fluorescent protein (CFP)-
and HA-tagged UGT1A1s were simultaneously expressed in
COS cells, anti-HA beads immunoprecipitated both CFP-
and HA-tagged UGT1A1s (Operaña and Tukey, 2007). Taken
together, immunoaffinity purification and immunoprecipitation
assays are typical but still powerful tools to demonstrate homo-
and hetero-oligomerization of UGTs. Immunoprecipitation
assays by Bellemare et al. (2010) further revealed that
inactive UGT1A_i2 proteins form not only homo-oligomers
(i2-i2) but also hetero-oligomers with UGT1A_i1 proteins
(i1-i2).
Fluorescence Resonance Energy
Transfer (FRET)
To examine UGT–UGT interactions in intact cells, Operaña
and Tukey (2007) conducted a FRET analysis using cyan and
yellow fluorescent proteins (CFP and YFP)-tagged recombinant
human UGTs expressed in COS cells. When correction for donor
and acceptor bleed through was performed and FRET signal
was analyzed, it was revealed that the two fusion UGT proteins
resided within ångströms from each other. Their FRET analysis
demonstrated homo-oligomerization of all UGT1A isoforms
as well as hetero-oligomerization of UGT1A1 with the other
UGT1A isoforms. The FRET analysis conducted by a different
research group indicated that not only UGT1As, but also human
UGT2B7 formed homo-oligomers in SF9 cells (Yuan et al., 2015;
Liu Y.Q. et al., 2016).
REGIONS AND AMINO ACID RESIDUES
RESPONSIBLE FOR OLIGOMERIZATION
OF UGTs
Importance of N-terminal Domain
To examine the region responsible for the oligomerization
of UGTs, Meech and Mackenzie (1997) constructed a couple
of chimeric rat UGT2B1 proteins fused with ecdysteroid
glucosyltransferase (EGT), which does not oligomerize.
While intact UGT2B1 formed dimers, the dimerization was
not observed when the C-terminal half of UGT2B1 was
fused with the N-terminal half of EGT. In 2001, two-hybrid
analysis by Ghosh et al. (2001) showed that UGT1A1s that
were mutated or partially deleted in their N-terminal region
(L175E, C233Y, or del152-180) abolished the ability to form
homo-oligomers, while UGT1A1 with partial truncation
of the C-terminal (K530X) still formed homo-oligomers
(Ghosh et al., 2001). These data indicated that the N-terminal
domains are involved in oligomerization of mammalian
UGTs.
Hydrophobic Amino Acids on the
Surface of Modeled UGT2B7
Hydrophobic amino acid residues on the surface of proteins
can mediate protein–protein interactions by introducing proline
brackets and pi–pi interactions. To identify such hydrophobic
amino acid residues of UGTs, Lewis et al. (2011) obtained a
three-dimensional structure of human UGT2B7 by homology
modeling (Table 1). In the homology-modeled structure of
human UGT2B7, a cluster of highly hydrophobic amino acid
residues on a B′-C loop (amino acid residues 183–200) was
located on the protein surface (Lewis et al., 2011). Thus, not
only in vitro studies, but in silico structural analyses also
supported the involvement of the N-terminal region of UGTs in
oligomerization.
PROTEIN–PROTEIN INTERACTIONS OF
UGTS WITH OTHER PROTEINS
Protein Interactions with CYPs
Cytochrome P450s are phase I drug-metabolizing enzymes that
are expressed in the ER membrane. To investigate the possible
protein-interactions between UGTs and CYPs, Taura et al.
(2000) applied solubilized rat liver microsomes to a CYP1A1-
conjugated Sepharose 4B column. It was found that multiple
UGT isoforms were co-eluted in a fraction where CYP1A1
was eluted. Rat UGTs were detected in immunoprecipitates
when solubilized rat liver microsomes were reacted with specific
antibodies against CYP3A2, CYP2B2, CYP2C11, and CYP1A2
(Ishii et al., 2007). Antibodies against human UGT2B7 and
CYP3A4 immunoprecipitated not only their antigenic proteins
but also CYP3A4 and UGT2B7, respectively, in solubilized
human liver microsomes (Fremont et al., 2005; Takeda et al.,
2005, 2009). These data indicate that mammalian UGTs interact
with CYPs in liver microsomes. It remains to be determined
whether such UGT-CYP interactions can still be observed in a
reconstituted system.
Protein Interactions with Microsomal
Proteins
Immunoprecipitation assay with human UGT2B7 antibody
was conducted using solubilized human liver microsomes.
The obtained immunoprecipitate was digested with trypsin,
and the resulting peptides were analyzed by LC-MS/MS to
identify proteins interacting with UGT2B7 in human liver
microsomes (Fujiwara and Itoh, 2014). The extensive peptide
analysis showed that the peptide sequences of UGT2B7, epoxide
hydrolase 1, carboxylesterase 1, alcohol dehydrogenases, and
glutathione S-transferases, as well as CYPs, were included
in the immunoprecipitates. It was confirmed that such
peptide sequences were not detected in immunoprecipitates
obtained with a control rabbit IgG antibody. Therefore,
UGT2B7 might be able to form a metabolosome, which is
a functional unit of metabolism (Mori et al., 2011) in liver
microsomes.
Protein Interactions with Cytoplasmic
Proteins
In contrast to normal UGT1A proteins (UGT1A_i1) that
are expressed in the luminal side of the ER membrane, a
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portion of UGT1A_i2 is cytoplasmic (Lévesque et al., 2007).
Immunoprecipitates of solubilized human intestine and kidney
homogenates with anti-UGT1A_i2 antibody were applied to
a global peptide analysis (Rouleau et al., 2014). It was
found that cytoplasmic catalase and peroxiredoxin 1 were co-
immunoprecipitated with UGT1A_i2 proteins in both tissues,
indicating that the truncated UGT1A isoform 2 is interacting
with those cytoplasmic proteins. Since such protein–protein
interactions were not observed when anti-UGT1A_i1 antibody
was used, the interactions with cytoplasmic proteins would be
specific to UGT1A_i2 proteins.
PHYSIOLOGICAL SIGNIFICANCE OF
OLIGOMERIZATION AND
PROTEIN–PROTEIN INTERACTIONS OF
UGTs
Impact of UGT–UGT Interactions on the
UGT-Mediated Glucuronidations
To investigate the effect of UGT–UGT interactions on the UGT
activities, Ishii et al. (2001, 2004) cloned guinea pig UGT2B21
and UGT2B22 and examined morphine 6-O-glucuronidation
in COS-7 cells expressing these UGTs. While UGT2B21
glucuronidates morphine, UGT2B22 does not have such ability
to glucuronidate morphine. Morphine 6-glucuronide formation
was 4.5-fold higher in COS-7 cells co-transfected with UGT2B21
and UGT2B22 compared to that in the cells transfected with
UGT2B21 alone, indicating that protein–protein interactions
between UGT2B21 and UGT2B22 upregulated the UGT activities
(Ishii et al., 2001, 2004). This observation led us to investigate
the impact of UGT–UGT interactions on the enzyme activities
in humans (Fujiwara et al., 2007b; Nakajima et al., 2007).
When we established stable expression systems of double
human UGT1As in HEK293 cells, the S50 value of UGT1A1-
mediated bilirubin glucuronidation was decreased by twofold
by the co-expressions of UGT1A4 or UGT1A6 (Fujiwara et al.,
2007a). A similar decrease of the S50 value was observed in
the UGT1A1-mediated estradiol 3-O-glucuronidation in a co-
expression system of UGT1A1 and UGT2B7 in HEK293 cells
(Fujiwara et al., 2010a). These data showed that substrate-
binding affinity of UGT1A1 toward bilirubin and estradiol
was increased when UGT1A1 was co-expressed with UGT1A4,
UGT1A6, and UGT2B7. Meanwhile, co-expression of UGT1A9
decreased the Vmax value of UGT1A1-mediated estradiol 3-O-
glucuronidation without affecting the S50 value (Fujiwara et al.,
2007b). Kurkela et al. (2004) demonstrated that the rate of
UGT1A9-catalyzed scopoletin glucuronidation was significantly
decreased by co-expression of UGT1A4. Thus, UGT–UGT-
interactions can modulate the catalytic rate of glucuronidation
as well as the affinity of substrates toward UGTs. Importantly,
the effects are dependent on interacting UGT isoforms and
compounds used as substrates.
Interestingly, even though sorafenib is mainly metabolized
by UGT1A9, it was demonstrated that the AUC of sorafenib
was twice higher in patients with UGT1A1 variants or with
hyperbilirubinemia (Peer et al., 2012). This finding indicates that
UGT1A1 might control the enzyme activity of UGT1A9 in vivo
by interacting with UGT1A9.
Although UGT1A_i2 proteins carry a potential UDP-
glucuronic acid binding-site, they do not show substantial
glucuronidation activity. As described above, the inactive
UGT1A_i2 proteins form hetero-oligomers with functional
UGT1A_i1 proteins. It was shown that glucuronide formation
mediated by UGT1A_i1 proteins was significantly suppressed
when UGT1A_i2 was co-expressed with UGT1A_i1 (Bellemare
et al., 2010). The expression level and the ratio of UGT1A_i1 and
_i2 are different in each tissue (Girard et al., 2007), suggesting
that UGT1A_i2 can be a factor suppressing the glucuronidation
in certain tissues. Interestingly, such suppression of UGT1
activity can also be caused by a truncated mutant of UGT1A1
(Gln331Stop; C to T at nucleotide 991), possibly by forming
oligomers (Koiwai et al., 1996).
Impact of UGT-CYP Interactions on the
UGT Activities
While a Km value of morphine 3-glucuronide formation was
0.38 mM in UGT2B7-expressing COS-1 cells, a much higher
Km value (3.7 mM) was observed in UGT2B7 and CYP3A4 co-
expressing cells (Takeda et al., 2005). In contrast, co-expression
of CYP1A2 or CYP2C9 did not affect the kinetic parameters
of UGT2B7-catalyzed morphine 3-glucuronide formations. In
addition, co-expression of CYP3A4 increased a Km value of
UGT1A6-mediated serotonin glucuronidation by ∼fourfold,
whereas it barely affected Km values of UGT1A1-mediated
4-MU, SN-38-, or estradiol 3-O-glucuronidations as well as
UGT1A7-mediated 4-MU, SN-38-, and 4-hydroxybiphenyl-
glucuronidations (Ishii et al., 2014). Meanwhile, co-expression
of CYP3A4 increased Vmax values of UGT1A1-mediated 4-MU,
SN-38-, and estradiol 3-O-glucuronidations, UGT1A6-mediated
serotonin glucuronidation, and UGT1A7-mediated 4-MU, SN-
38-, and 4-hydroxybiphenyl-glucuronidations, although it did
not affect the UGT2B7-mediated morphine 3-glucuronidation
(Takeda et al., 2005; Ishii et al., 2014). Therefore, CYP
isoforms differently affect UGT-mediated glucuronidations and
the effects are depending on UGT isoforms as well as their
substrates.
Effect UGTs on Other Physiological
Functions
Interestingly, a more than 40-fold interindividual variability
in UGT1A6-catalyzed serotonin glucuronidation was observed
among individual human liver microsomes (Krishnaswamy
et al., 2003, 2005). Such variability could not be explained
even when the activities were normalized with the UGT1A6
content and its genetic polymorphisms, indicating that there
might be some unidentified factor that is capable of modulating
the UGT1A6 activity. Since CYP isoforms can modulate UGT
activities in different ways, interindividual variability in the CYP
expression and function might be one of the causes of these
wide interindividual variabilities in UGT1A6-catalyzed serotonin
glucuronidation.
Frontiers in Pharmacology | www.frontiersin.org 9 October 2016 | Volume 7 | Article 388
fphar-07-00388 October 20, 2016 Time: 17:9 # 10
Fujiwara et al. Structure and Protein–Protein Interactions of Human UGTs
Miyauchi et al. (2015) investigated the effect of UGT2B7
on CYP3A4 activities by establishing a co-expression system
of UGT2B7 and CYP3A4. They found that co-expression of
UGT2B7 significantly decreased the Vmax value of CYP3A4
activity without affecting a Km value using luciferin-6′-
pentafluorobenzyl ether as a substrate. Similarly, co-expression
of UGT2B7 decreased the CYP3A4-mediated testosterone 6β-
hydroxylation at a single substrate concentration (Miyauchi et al.,
2015). These observations indicated that UGTs might suppress
the enzyme activities of CYPs.
In a recent study by Liu M. et al. (2016), it was demonstrated
that silencing of UGT1A expressions led to inhibitions of
actinomycin D- and etoposide-induced p53 expressions in
human colon HT29 and LS180 cells. Tissue-specific deletion of
the Ugt1 locus in intestinal crypt stem cells not only reduced
p53 activation, but also compromised apoptosis. It was further
demonstrated that reduced expression of UGT1A in intestine
caused greater size and number of tumors in the colon cancer
models (Liu M. et al., 2016).
When UGT1A_i2 was knocked-down in colorectal
carcinoma-derived HT115 cells, expressions of a number of
genes were up- or down-regulated (Rouleau et al., 2014).
Among those genes, hemoglobin-alpha was significantly
induced by the knockdown of UGT1A_i2. The function
of hemoglobin-alpha proteins has been linked to cellular
antioxidant potential (Widmer et al., 2010). Furthermore, it was
found that knocked-down of UGT1A_i2 reduced a chemical-
induced ROS formation in HT115 cells and significantly induced
superoxide dismutase 1, an antioxidative gene. Although the
underlying mechanism of induction of hemoglobin-alpha by
knockdown of UGT1A_i2 is still unknown, the observation
clearly indicates that UGT1A_i2 proteins are involved in the
regulation of oxidative stress in cells. Taking all these findings
together, it appears that UGTs are multifunctional proteins that
controls metabolism, cell death and development of tumors, and
oxidative stress.
CRITIQUE AND FUTURE RESEARCH
DIRECTIONS
Protein Structure of UGTs
Various three-dimensional structures of human UGTs have
been simulated by homology modeling (Table 1) and they are
relatively acceptable as mentioned above. However, due to the
extremely low amino acid similarity and different length of
the amino acid sequence between human UGTs and template
plant and bacterial UGTs, the reliability of the modeled human
UGT protein structures is still an open question. Indeed, it
is generally believed that the identity of amino acid sequence
with the template needs to be more than 70% to obtain
reliable structure. Furthermore, there is a significant structural
difference between human and plant/bacterial UGTs that human
UGTs are membrane proteins while plant and bacterial UGTs
are not. To obtain a completely reliable modeled structure of
human UGTs, an X-ray crystal structure of human UGTs needs
to be successfully solved. Importantly, as mammalian UGTs
abolish their enzyme activities when they are solubilized, a
solubilized and crystallized structure of human UGTs might
be an enzymatically inactive form. The instability of the
protein structure of human UGTs can also be an obstacle
in crystallizing them. Interestingly, UGT1A9 solely exhibited
its enzymatic activity in the presence of 0.2% Triton X-100,
although activities of other UGT1A and 2B isoforms were
abolished by the detergent treatment (Kurkela et al., 2003).
Human UGT1A9 is uniquely stable against a heat treatment as
well (Fujiwara et al., 2009a), indicating that the protein structure
of UGT1A9 must be more stable than the structures of other UGT
isoforms. Therefore, human UGT1A9 is a promising human
UGT isoform that has a potential to be crystallized as an active
form.
Oligomerization of UGTs In vivo
Gel filtration and radiation inactivation analyses, where
the liver microsomes were mixed with detergents, showed
that monomeric UGTs catalyzed glucuronidation of certain
compounds. It is well known that detergents can disrupt
oligomerization of proteins; therefore, the monomeric UGTs
might have been artificially generated from disruption of UGT
oligomers. While SDS-PAGE shows the molecular weight of
individual subunits of proteins under the reduced and denatured
condition, oligomerization can be preserved in native-PAGE
analysis. Our native-PAGE analysis of recombinant human
UGTs expressed in HEK293 cells showed that most of UGTs
were present as monomers, whereas some of them were
still forming oligomers (Figure 4) (Fujiwara et al., 2007a).
However, again, such monomers could have been a result from
disruption of oligomeric UGTs due to a fact that the native-PAGE
experiment required 1% Triton X-100 and 0.2% SDS to slightly
solubilize the cell homogenates. Therefore, it is unclear whether
UGTs dominantly exist as oligomer or monomer in intact
cells.
Fluorescence resonance energy transfer is an analytical tool
to demonstrate oligomerization of proteins in intact cells.
Interestingly, FRET efficiency, which is a marker for co-
localization and interaction, was 90% in COS cells expressing
CFP- and YFP-tagged UGT1A7s (Operaña and Tukey, 2007),
indicating that most of UGT1A7 was interacting with each
other to form oligomers in intact cells. Meanwhile, the FRET
efficiency was lower in certain UGT1A isoforms such as UGT1A3
and UGT1A9. These observations indicate that UGTs would
exist as both monomeric and oligomeric forms in intact cells
with variable extent depending on UGT isoforms. A limitation
of the FRET analysis is that tagged UGT proteins, not intact
proteins, were used. Therefore, determination of the extent of
monomeric/oligomeric forms of intact UGT in cellulo is a future
issue.
Availability and Application of Ugt1 and
Ugt2 Knockout Mice
Various data indicate that UGTs can be multifunctional
proteins that are involved in cellular metabolism, apoptosis,
carcinogenesis, and oxidative stress as well as glucuronidation.
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FIGURE 4 | Native PAGE analyses of UGT1A isoforms in single or
double expression systems. Single or multiple UGT1A isoforms were stably
expressed in HEK293 cells. Total cell homogenates were solubilized with 1%
Triton X-100 and 0.2% SDS, and then were subjected to a native gel.
Immunoblotting was conducted with rabbit anti-human UGT1A antibody. The
bands with closed and open arrowheads indicate homo- and hetero-dimers,
respectively. Hetero-dimer was detected in the double expression system of
UGT1A1 and UGT1A4, while such oligomer was not observed when single
expression systems of UGT1A1 and UGT1A4 were mixed. Adapted from Drug
Metabolism and Disposition (Fujiwara et al., 2007a).
However, these unique properties of UGTs have not been fully
validated by in vivo data. Ugt1- and Ugt2-knockout animals
are promising in vivo models for investigating the roles of
UGTs in such cellular metabolism, apoptosis, carcinogenesis,
and oxidative stress. With extensive efforts by Drs. Tukey and
Koller and their colleagues, Ugt1- and Ugt2-knockout mice were
previously developed in 2008 and 2015, respectively (Nguyen
et al., 2008; Fay et al., 2015). While Ugt2 knockout mice
can be used for the phenotype analysis, Ugt1 knockout mice
are lethal within 11 days after birth due to development of
a bilirubin-induced irreversible brain damage, kernicterus. To
conduct phenotype analyses in Ugt1 knockout mice, therefore,
we need to first avoid the lethality of the mice. Inhibitors of
bilirubin production and inducers of bilirubin clearance might
have potentials to rescue the lethality of the Ugt1 knockout
mice.
Possible Role of UGTs in Transport of
UGT Substrates and Metabolites
Transporters responsible for the uptake of the co-substrate
UDP-glucuronic acid from cytosol to the luminal side of
ER membrane have been identified (Muraoka et al., 2001).
Although studies suggested that there are proteins that are
involved in the eﬄux of hydrophilic glucuronide across the
ER membrane (Bánhegyi et al., 1996; Csala et al., 2004), such
transporter(s) has not been identified. As shown in Figure 5, it
was originally hypothesized that oligomerization and/or protein–
protein interactions of UGTs have a role in transporting
glucuronides across the ER membrane (Lin and Wong, 2002; Ishii
et al., 2005); however, such evidence has not yet been obtained.
Even in the immunoprecipitates of liver microsomes with
anti-UGT2B7 antibody, no peptide sequences of transporters
was observed (Fujiwara and Itoh, 2014). Further studies are
required to fully understand the detailed information on the
FIGURE 5 | Proposed model of oligomeric human UGTs. Human UGTs form homo- and hetero-oligomers in ER membrane. As indicated with blue arrows,
oligomerization of UGTs might be involved in the transport of substrates and glucuronides across the ER membrane. Protein–protein interactions of human UGT with
other microsomal and cytoplasmic proteins such as UGT, CYP, and p53 can make a great impact on glucuronidation, oxidation, apoptosis, carcinogenesis, and
oxidative stress.
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transport of UGT substrates and their metabolites across the ER
membrane.
CONCLUSION
In addition to enzyme inhibition and induction, oligomerization
is a predominant factor regulating the function of UGTs.
UGTs are multifunctional proteins that are involved not
only in glucuronidation, but also in cellular metabolism,
apoptosis, carcinogenesis, and oxidative stress in the human
body (Figure 5). Global protein interactions of UGTs with other
microsomal or cytoplasmic proteins might be a contributing
factor to a wide interindividual variability in UGT-catalyzed
glucuronidations.
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